News

54 new multiple sclerosis (MS) research and development initiatives are set to receive substantial funding in order to accelerate new therapies. The National Multiple Sclerosis Society (NMSS) announced that it has pledged $19 million to fund these new MS studies as part of their mission to better manage…

Genzyme, a Sanofi company, has announced that the Canadian province of Québec’s Institut national d’excellence en santé et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “Médicament d’exception” as a second-line treatment for…

Recent research reveals that placenta-based cell therapy is both safe and effective for treating both Relapsing-Remitting and progressive forms of MS. A new study entitled “Human Placenta-Derived Cells (PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Study” and published in August…

A new study, entitled “The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis” published online in JAMA Neurology, reports the effect of Glatiramer acetate therapy on B cells in relapsing-remitting multiple sclerosis (MS) patients. This first-of-its-kind study could…

San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed a Sponsored Research Agreement with Fast Forward, a non-profit organization that aims to accelerate MS treatment development. Glialogix will receive funding for one of their…

Multiple sclerosis (MS) is a chronic, autoimmune neurodegenerative disease that the biomedical research and pharmaceutical industry has yet to find a cure for. It is a progressively debilitating condition that manifests with a number of unpredictable symptoms that can greatly reduce one’s quality of life. In order…

A new study conducted at the Department of Rehabilitation and Movement Science of the University of Vermont, reinforces the idea that multiple sclerosis patients can handle exercise regimens, despite their mobility difficulties, in order to improve not only their motor capacities, but also their quality of life. Although over 90% of…

In today’s healthcare environment, it is often not enough that patients are provided with the latest treatments. Good health is not merely the absence of injury or disease, but overall wellness that includes mental, spiritual and social health. A group of investigators from the Kessler Foundation…

With multiple sclerosis (MS) prevalence rates still at concerning levels of 90 for every 100,000 Americans, researchers are continuously seeking to learn more about the disease, and are aggressively working to develop novel treatments and interventions for symptom management. This poses an ongoing challenge for healthcare professionals and academics,…

Funding for continued research and development into understanding, treating, and eventually curing Multiple Sclerosis continues to accelerate. Evotec AG, a German company that specializes in providing drug discovery resources to pharmaceutical and biotech companies, and learning institutions, has just announced the launch of its line-up of groundbreaking studies into MS — an…

MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the…

Deepelling International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope for MS patients all over the world. Quebec is one of North America’s epicenters for MS research and developments. This year, on…

A vaccination against multiple sclerosis is in progress in the laboratory of SangKon Oh, PhD, at the Baylor Institute for Immunology Research. Along with Gerard Zurawski, PhD, and Ted Phillips, MD, Dr. Oh is applying new insights from research in dendritic cell vaccines to a multiple sclerosis vaccine. “Dr.

For the first time, an antisense oligonucleotide has been shown to be effective in treating relapse-remitting multiple sclerosis. A phase 2a clinical trial of Antisense Therapeutics Limited’s ATL1102, a CD49d antisense drug, showed that the treatment quickly reduced brain lesions in RRMS patients following the start of therapy.

Researchers are continuing to make headway in discovering new insights into how MS works, which in turn could lead to next-generation therapies. A new study shows that in the early stages of multiple sclerosis (MS), plasma micro particles act as biomarkers as well as pathological factors that induce endothelial permeability and…

Joy Nabors – The Raw Beauty Project NYC model living with Multiple Sclerosis In a bold movement aimed towards empowering disabled women to stand against social stigmas, the Christopher & Dana Reeve Foundation partnered with innovative visual arts project, Raw Beauty Project NYC, to showcase a series of photographs…

Phase 3 clinical trial results from Biogen Idec and AbbVie presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRMIS) suggest that relapsing-remitting multiple sclerosis patients experience…

The nonprofit organization Accelerated Cure Project for Multiple Sclerosis is going to sponsor the launch of the Optimizing Treatment – Understanding Progression (OPT-UP) study in collaboration with biopharmaceutical company EMD Serono, Inc, a subsidiary of the german Merck KGaA. The study will enroll 2,500 MS…

MuckFest® MS runners getting down and dirty for a cause. One of the more engaging ways to campaign for awareness and fundraising for a disease is hosting a sporting event. Be it a marathon, weight lifting, biking, or even ziplining, adding an element of fun in supporting a serious…

Trying to nail down the reason for executive deficits in multiple sclerosis can be difficult, considering the number of factors related to the condition. A team of researchers from the Kessler Foundation — led by Victoria Leavitt, PhD, who is now a part of the Manhattan Memory Center, and…

The first round of 22 research grants have been awarded to projects in nine countries by the International Progressive MS Alliance, with the goal of removing barriers to developing treatments for progressive MS. The 22 projects were chosen from 195 research proposals submitted by researchers in 22 countries and…

The underlying cause of fatigue experienced by multiple sclerosis (MS) patients may be undiagnosed sleep disorders, according to a study conducted at the Department of Neurology of the University of California. Not only is that a problem in itself, but also an undiagnosed and untreated sleeping disorder may exacerbate the…

Biogen Idec revealed data from its second year of the phase 3 ADVANCE clinical trial for the study of Plegridy as a treatment for patients with relapsing forms of multiple sclerosis, which demonstrated the positive effects of the subcutaneous injectable therapy beyond the first year…

Biopharmaceutical company Merck Serono, a division of Merck, recently awarded a total of €1 million to the five winners of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at MS Boston 2014, the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee…

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), together with Active Biotech (NASDAQ OMX NORDIC:ACTI), presented new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS)…

Biogen Idec presented the five-year results from its ENDORSE phase 3 extension study of Tecfidera (dimethyl fumarate), which revealed that the treatment is able to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’s ACTRIMS-ECTRIMS summit. Not only did…

This past Wednesday, September 10th, the largest, most anticipated multiple sclerosis (MS) convention — the 6th Joint ACTRIMS-ECTRIMS Triennial Meeting, MSBoston 2014 — kicked off with a whopping 8,000 registered attendees, all eager to learn more about the latest developments in MS. One of the highlights of the event…

During the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place in Boston from September 10-13, EMD Serono, Inc., a subsidiary of Merck KGaA, will present new data from its multiple sclerosis…

Acorda Therapeutics will present results of a study analyzing AMPYRA (dalfampridine) Extended Release Tablets in multiple sclerosis patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, held through September 10-13. Unlike many other studies of therapeutic agents, this study looked at prescribing patterns, patient compliance, and budget impact…

Biopharmaceutical company Receptos, Inc. announced that they will review data from the phase 2 portion of the RADIANCE trial, the company’s phase 2 / 3 study testing RPC1063 in the treatment of Relapsing Multiple Sclerosis (RMS). The data is being presented at the largest meeting dedicated to multiple sclerosis…